Skip to main content
. 2022 Feb 9;40(2):269–279. doi: 10.1002/hon.2964

FIGURE 6.

FIGURE 6

Occurrence of Observed Treatment‐Emergent Grade 3 or Worse Adverse Events and 95% Binomial CIs for Venetoclax Plus LDAC by Venetoclax AUCss Quartiles (A) Neutropenia, (B) Thrombocytopenia, (C) Infections. AUCSS, area under the plasma concentration‐time curve at steady state; CI, confidence interval; LDAC, low‐dose cytarabine